[go: up one dir, main page]

WO2008038160A3 - A substance with sedative effect for use in the treatment of neurotic disorders - Google Patents

A substance with sedative effect for use in the treatment of neurotic disorders Download PDF

Info

Publication number
WO2008038160A3
WO2008038160A3 PCT/IB2007/004218 IB2007004218W WO2008038160A3 WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3 IB 2007004218 W IB2007004218 W IB 2007004218W WO 2008038160 A3 WO2008038160 A3 WO 2008038160A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
patients
pyrone
gamma
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004218
Other languages
French (fr)
Other versions
WO2008038160A2 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technology Commercialization Corp
Original Assignee
Technology Commercialization Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/459,659 external-priority patent/US20060252824A1/en
Application filed by Technology Commercialization Corp filed Critical Technology Commercialization Corp
Publication of WO2008038160A2 publication Critical patent/WO2008038160A2/en
Publication of WO2008038160A3 publication Critical patent/WO2008038160A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A substance with sedative effect comprises a therapeutically effective amount of a gamma- pyrone such as comenic acid, meconic acid, 5-methoxy-gamma-pyrone-2-carboxylic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose of a patient, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
PCT/IB2007/004218 2006-07-25 2007-06-21 A substance with sedative effect for use in the treatment of neurotic disorders Ceased WO2008038160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/459,659 US20060252824A1 (en) 2002-03-19 2006-07-25 Substance with sedative effect
US11/459,659 2006-07-25

Publications (2)

Publication Number Publication Date
WO2008038160A2 WO2008038160A2 (en) 2008-04-03
WO2008038160A3 true WO2008038160A3 (en) 2008-07-24

Family

ID=39230613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004218 Ceased WO2008038160A2 (en) 2006-07-25 2007-06-21 A substance with sedative effect for use in the treatment of neurotic disorders

Country Status (1)

Country Link
WO (1) WO2008038160A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079976A2 (en) * 2002-03-19 2003-10-02 Technology Commercialization Corp. A substance with sedative effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003079976A2 (en) * 2002-03-19 2003-10-02 Technology Commercialization Corp. A substance with sedative effect
US20060252824A1 (en) * 2002-03-19 2006-11-09 Krylov Boris V Substance with sedative effect

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DERBENEV A V ET AL: "Effects of meconic and comenic acids on slow sodium channels of secondary neurons.", MEMBRANE & CELL BIOLOGY 2000, vol. 13, no. 3, 2000, pages 379 - 387, XP009098978, ISSN: 1023-6597 *
ROGACHEVSKII I V ET AL: "Quantum-chemical study of the equilibrium geometry and electronic structure of certain [gamma]-pyrone derivatives", RUSSIAN JOURNAL OF GENERAL CHEMISTRY, NAUKA/INTERPERIODICA, MO, vol. 76, no. 11, 1 November 2006 (2006-11-01), pages 1820 - 1833, XP019468092, ISSN: 1608-3350 *
V. ROGACHEVSKY, V. B. PLAKHOVA, S. A. PODZOROVA: "METAL-BOUND FORMS OF 4H-PYRAN-4-ONE DERIVATIVES MODULATE NOCICEPTIVE RESPONSES OF SENSORY NEURONS", TECHNOLOGIES OF THE 21ST CENTURY-BOOK OF ABSTRACTS, 27 September 2005 (2005-09-27), pages 77 - 80, XP002477283, Retrieved from the Internet <URL:http://www.infran.ru/meetings/Abstracts-AvH.pdf> [retrieved on 20080418] *

Also Published As

Publication number Publication date
WO2008038160A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
US6271240B1 (en) Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
JP4898073B2 (en) Fentanyl composition for intranasal administration
CN101534809B (en) Use of substituted 2-amino-1,2,3,4-tetralin in the preparation of medicines for preventing, alleviating and/or treating various types of pain
MX2009009131A (en) Improvements in and relating to medicinal compositions.
WO2003080022A3 (en) Analgesics for nasal administration
JP2006231070A5 (en)
WO2007098479A3 (en) Localized insulin delivery for bone healing
JP5306207B2 (en) Use of opioid formulations in needle-free drug delivery devices
HRP20140592T1 (en) IMPROVED MEDICINAL PRODUCTS CONTAINING BUPRENORPHINE AND NALTREXONE
WO2003079976A3 (en) A substance with sedative effect
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
US20150352040A1 (en) Topical peripheral neuro-affective (tpna) therapy
JP4173538B2 (en) Nasal and ophthalmic administration of ketamine for pain management and detoxification
EP1295598A1 (en) Pharmaceutical composition containing two active ingredients for smoking cessation
CN104758445A (en) Tobacco leaf extract, uses thereof in treatment of dependence
JP5134973B2 (en) Method of treatment with combination of medicines and combination of medicines suitable therefor
Maseeh et al. A review of smoking cessation interventions
WO2008038160A3 (en) A substance with sedative effect for use in the treatment of neurotic disorders
ES2274064T3 (en) COMBINATION OF ACTIVE PRINCIPLES FOR DRUG THERAPY OF NICOTINE DEPENDENCE.
US20160058701A1 (en) Vaporized Medicants and Methods of Use
Bentz Clonidine is more effective than placebo for long-term smoking cessation but has side effects/COMMENTARY
US20160058752A1 (en) Topical peripheral neuro-affective (tpna) therapy for neuropathic conditions
Wilken et al. Smoking cessation—part III: pharmacotherapy of smoking cessation
Cashman Routes of administration
CN1674911A (en) Medicament and method for reducing alcohol and/or tobacco consumption

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07859265

Country of ref document: EP

Kind code of ref document: A2